Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 9/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924279 | 0.84 | SHMT2 (0.39) | P2RX7 | |
| SCHEMBL3721635 | 0.82 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL21758437 | 0.80 | BAZ2B (0.40) | F12P2RX7 | |
| SCHEMBL19637802 | 0.78 | KDM4E (0.42) | — | |
| SCHEMBL1832511 | 0.77 | PARP1 (0.47) | F12P2RX3 | |
| SCHEMBL19547102 | 0.74 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL28894031 | 0.74 | C5AR1 (0.32) | P2RX7 | |
| SCHEMBL29493385 | 0.73 | SMYD3 (0.43) | CNR2 | |
| SCHEMBL18343220 | 0.72 | NOTUM (0.35) | — | |
| SCHEMBL23928082 | 0.72 | KDM4E (0.44) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| EP-3841102-B1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2022-09-14 | — | — | EP | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-10-28 | — | — | US | disclosed |
| EP-3841102-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020039093-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039093-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332041-A1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | AHR, ARNT, NQO1 | F12 4733/4885GPR6 211/4885P2RX7 979/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | F12 4733/4885GPR6 211/4885P2RX7 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.